Substance Use Disorder Treatment Denied? MHPAEA, ASAM Criteria, and the Wit v. UBH Case

Substance use disorder treatment denials are among the most consequential insurance decisions an insurer can make. Denial of detox, residential treatment, intensive outpatient programming, or medication-assisted treatment can cost lives. If your insurer denied SUD treatment, you have strong federal legal rights and important case law on your side. This guide explains the complete appeal strategy for SUD treatment denials.

Why Insurers Deny SUD Treatment

Mental Health Parity Act (MHPAEA) Explained" class="auto-link">MHPAEA parity violations — the most common and legally actionable basis. Under the Mental Health Parity and Addiction Equity Act (29 U.S.C. § 1185a; 42 U.S.C. § 300gg-26), SUD treatment benefits must be covered no less generously than comparable medical and surgical benefits. Common parity violations include: requiring Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization for residential SUD treatment when no comparable authorization is required for inpatient medical rehabilitation; applying more restrictive medical necessity criteria for inpatient SUD treatment than for inpatient medical care; and limiting residential SUD stays to 30 days when comparable medical residential care has no day limit.

Level of care disputes — residential vs. outpatient. The most common denial pattern is a step-down dispute: the insurer approves IOP rather than residential treatment, or discharges a patient from residential care prematurely. These denials are directly challenged by showing that the ASAM Criteria support the recommended level of care and that the insurer's internal criteria are more restrictive without clinical justification.

Internally developed criteria more restrictive than ASAM. Insurers often apply proprietary clinical criteria that conflict with the ASAM Criteria. The Consolidated Appropriations Act of 2021 (CAA 2021) requires plans to conduct and document non-quantitative treatment limitation (NQTL) comparative analyses. Plans that cannot produce this document are presumptively violating MHPAEA.

MAT denials through PA obstacles and formulary restrictions. Buprenorphine, methadone, and naltrexone are FDA-approved, life-saving medications for opioid use disorder. MHPAEA parity requires that MAT medications face no more restrictions than comparable medical drug treatments. Prior authorization requirements, visit limits, and formulary restrictions that are not applied to comparable medical medications are parity violations.

How to Appeal a SUD Treatment Denial

Step 1: Identify the Parity Violation

Compare the treatment limitation being applied to your SUD benefit with how the plan treats a comparable medical or surgical benefit. For example: does the plan require prior authorization for residential SUD treatment but not for inpatient medical rehabilitation? Does the plan limit residential SUD coverage to 30 days but impose no such day limit for inpatient cardiac rehabilitation? If you can identify a more favorable comparable medical benefit, you have a MHPAEA parity violation.

Step 2: Request the NQTL Comparative Analysis

Write to the plan administrator requesting the non-quantitative treatment limitation (NQTL) comparative analysis required by CAA 2021. Under 29 CFR § 2590.712(c)(4), plans must provide this analysis upon request. Plans that cannot produce the analysis are in violation of federal law. This request alone often prompts plans to reconsider a denial rather than expose a parity violation.

Step 3: Document ASAM Criteria Support for the Recommended Level of Care

The ASAM Criteria evaluate six clinical dimensions: acute intoxication and withdrawal potential; biomedical conditions; emotional/behavioral/cognitive conditions; readiness to change; relapse/continued use potential; and recovery/living environment. Your addiction medicine physician or treatment provider should prepare a detailed ASAM dimensional assessment documenting why the recommended level of care is appropriate across each dimension. This directly challenges insurer criteria that recommend a less intensive level of care.

Step 4: Cite Wit v. United Behavioral Health

In Wit v. United Behavioral Health (N.D. Cal. 2019), a federal court found that UBH's internal behavioral health criteria were more restrictive than generally accepted standards of care, violating ERISA fiduciary duties and MHPAEA. The court established that insurers must use criteria consistent with generally accepted professional standards — not internally developed criteria designed to control costs. Cite Wit for the principle that the insurer's criteria must conform to the ASAM standard, not replace it with more restrictive internal criteria.

Step 5: Address MAT Denials Specifically

For medication-assisted treatment denials, SAMHSA, ASAM, and the American Society of Addiction Psychiatry all recommend buprenorphine, methadone, and naltrexone as first-line treatment for opioid use disorder. Cite MHPAEA parity: identify comparable medical drug treatments that face no more restrictions than MAT medications should face. For example, many plans cover cancer medications with straightforward prior authorization while imposing visit limits, patient counseling requirements, and frequent PA renewals on MAT prescriptions that are not applied to any comparable medical medication.

Step 6: Request External Independent Review: Complete Guide" class="auto-link">External Review and File Regulatory Complaints

If the internal appeal fails, request external independent medical review. For MHPAEA violations in ERISA-governed employer plans, file a complaint with the DOL's Employee Benefits Security Administration (EBSA). EBSA can investigate and compel plan compliance. For fully insured state-regulated plans, file a complaint with your state insurance department. Many states have strengthened MHPAEA enforcement in recent years.

What to Include in Your Appeal

• ASAM dimensional assessment from your addiction medicine physician documenting clinical support for the recommended level of care
• Written request for NQTL comparative analysis citing CAA 2021 requirements under 29 CFR § 2590.712(c)(4)
• Specific parity comparison identifying a more favorable comparable medical or surgical benefit
• Wit v. UBH citation for the generally accepted standards of care requirement
• Clinical records documenting diagnosis, prior treatment history, and current severity of substance use disorder

Fight Back With ClaimBack

SUD treatment denials involving MHPAEA parity violations, ASAM criteria disputes, and MAT medication restrictions require legally precise and clinically grounded appeals. ClaimBack generates professional SUD treatment appeal letters tailored to your specific denial. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal